| 连立芬,高亚梅,刘鑫,等.妊娠期糖尿病 126例孕中期血清 C1q/肿瘤坏死因子相关蛋白 5、C1q/肿瘤坏死因子相关蛋白 9水平变化及意义[J].安徽医药,2023,27(12):2456-2460. |
| 妊娠期糖尿病 126例孕中期血清 C1q/肿瘤坏死因子相关蛋白 5、C1q/肿瘤坏死因子相关蛋白 9水平变化及意义 |
| Changes and significance of serum CTRP5 and CTRP9 levels in the second trimester of gestational diabetes: a study of 126 cases |
| |
| DOI：10.3969/j.issn.1009-6469.2023.12.027 |
| 中文关键词: 糖尿病，妊娠 C1q/肿瘤坏死因子相关蛋白 5(CTRP5) C1q/肿瘤坏死因子相关蛋白 9 分娩结局 |
| 英文关键词: Diabetes, gestational C1q / tumor necrosis factor related protein 5 (CTRP5) C1q / tumor necrosis factor related pro. tein 9 Delivery outcomes |
| 基金项目:秦皇岛市科学技术研究与发展计划( 201805A071) |
|
| 摘要点击次数: 996 |
| 全文下载次数: 430 |
| 中文摘要: |
| 目的分析孕中期血清 C1q/肿瘤坏死因子相关蛋白 5(CTRP5)、 C1q/肿瘤坏死因子相关蛋白 9(CTRP9)水平对妊娠期糖尿病( GDM)病人围生儿不良结局的预测价值。方法选取秦皇岛市妇幼保健院 2019年 1月至 2020年 5月收治的 128例 GDM病人和 125例健康孕妇，分别记为疾病组和对照组。两组均采用酶联免疫法( ELISA)检测孕中期血清 CTRP5、CTRP9水平，比较两组不良结局、孕中期血清 CTRP5、CTRP9水平差异。比较疾病组结局良好与结局不良病人孕中期血清 CTRP5、 CTRP9水平，采用 logistic回归分析探讨疾病组结局不良的影响因素。绘制受试者操作特征( ROC)曲线，并用曲线下面积(AUC)评价血清 CTRP5、CTRP9单独及联合对疾病组围生儿不良结局的预测效能。结果疾病组有 2例失访，对照组有 1例失访，均剔除本研究，最终纳入本研究疾病组 126例，对照组 124例。疾病组围生儿不良结局发生率为 19.05%(24/126)高于对照组 2.42%(3/124)(P<0.05)；疾病组孕中期血清 CTRP5水平( 41.47±8.04)μg/L高于对照组( 21.06±4.55)μg/L，疾病组血清 CTRP9水平(101.25±22.36)ng/L低于对照组(157.83±29.73)ng/L，均差异有统计学意义(P<0.05)。高龄产妇、糖尿病家族史、孕前 BMI、孕中期血清 CTRP5水平、治疗依从、孕中期血清 CTRP9水平均是疾病组围生儿不良结局的影响因素；孕中期血清 CTRP5、 CTRP9水平联合预测围生儿不良结局，疾病组围生儿不良结局母体孕中期血清 CTRP5水平(73.69±8.76)μg/L高于围生儿结局良好母体( 33.89±4.15)μg/L(t=33.00，P<0.001)，血清 CTRP9水平( 60.88±12.71)ng/L低于围生儿结局良好母体( 110.75±23.58) ng/L(t=10.00，P<0.001)。结论 GDM病人孕中期血清 CTRP5水平偏高， CTRP9水平偏低，二者均是围生儿不良结局的影响因素，且联合预测该不良事件的效能高。 |
| 英文摘要: |
| Objective To analyze the predictive value of serum levels of C1q / tumor necrosis factor related protein 5 (CTRP5) andC1q / tumor necrosis factor related protein 9 (CTRP9) in the second trimester of pregnancy for perinatal adverse outcomes in patientswith gestational diabetes mellitus (GDM).Methods A total of 128 GDM patients and 125 healthy pregnant women admitted to Qin.huangdao Maternal and Child Health Hospital from January 2019 to May 2020 were selected and recorded as disease group and controlgroup, respectively. The serum levels of CTRP5 and CTRP9 in the second trimester of pregnancy were detected by enzyme-linked im. munosorbent assay (ELISA). The incidences of adverse perinatal outcomes, serum levels of CTRP5 and CTRP9 in the second trimesterof pregnancy were compared between the two groups. The serum levels of CTRP5 and CTRP9 in the second trimester of pregnancy werecompared between patients with good and poor outcomes in the disease group. Logistic regression analysis was made to explore the in.fluencing factors of poor outcomes in the disease group. The receiver operating characteristic curve (ROC) was drawn, and the area un.der the curve (AUC) was used to evaluate the predictive effect of serum CTRP5 and CTRP9 on perinatal adverse outcomes in the dis.ease group separately and jointly.Results Two patients were lost to follow-up in the disease group and one in the control group, whowere excluded from this study, and 126 patients in the disease group and 124 in the control group were included in the study. The inci.dence of adverse perinatal outcomes in the disease group was 19.05% (24/126), which was higher than that in the control group (2.42%,3/124), with a statistically significant difference (P<0.05). The level of serum CTRP5 in the second trimester of pregnancy in the dis.ease group was higher than that in the control group [(41.47±8.04) μg/L vs. (21.06±4.55) μg/L], while the level of serum CTRP9 in the disease group was lower than that in the control group [(101.25±22.36) ng/L vs. (157.83±29.73) ng/L], with statistically significant dif. ferences (P<0.05). Elderly parturient women, family history of diabetes, pre-pregnancy BMI, serum CTRP5 and CTRP9 levels in thesecond trimester of pregnancy, and treatment compliance were all factors influencing perinatal adverse outcomes in the disease group.The serum CTRP5 and CTRP9 levels were used jointly to predict adverse outcomes in perinatal infants. Serum CTRP 5 level was high.er than those with perinatal good outcomes [(73.69±8.76) μg/L vs. (33.89±4.15) μg/L] (t=33.00, P<0.001), while serum CTRP 9 level inparturient women with perinatal adverse outcomes in the disease group was lower than those with perinatal good outcomes [(60.88±12.71) ng/L vs. (110.75±23.58) ng/L] (t=10.00, P<0.001).Conclusions The serum level of CTRP5 in GDM patients in the second tri.mester of pregnancy is higher than those healthy pregnant women, and the serum level of CTRP9 is lower. Both of them are the influenc.ing factors of perinatal adverse outcomes, and the combined use of them for the prediction of the adverse events is more effective. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
